TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Sponsor: Cabaletta Bio · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 37 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,782,176

Rescue Site Savings

+$1,174,616

Unlock Full NCT06328777 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06328777 Rescue Dossier →